MMPs/TIMPs imbalances in the peripheral blood and cerebrospinal fluid are associated with the pathogenesis of HIV-1-associated neurocognitive disorders

[1]  R. Shawahna.  Physical and Metabolic Integrity of the Blood-Brain Barrier in HIV Infection: A Special Focus on Intercellular Junctions, Influx and Efflux Transporters and Metabolizing Enzymes. , 2015, Current drug metabolism.

[2]  Sunit K. Singh,et al.  HIV-1 Tat C phosphorylates VE-cadherin complex and increases human brain microvascular endothelial cell permeability , 2014, BMC Neuroscience.

[3]  S. Crowe,et al.  Monocytes as Regulators of Inflammation and HIV-Related Comorbidities during cART , 2014, Journal of immunology research.

[4]  S. Lakhan,et al.  Matrix Metalloproteinases and Blood-Brain Barrier Disruption in Acute Ischemic Stroke , 2013, Front. Neurol..

[5]  K. Spindler,et al.  Viral disruption of the blood-brain barrier. , 2012, Trends in microbiology.

[6]  Leah M. Alabanza,et al.  Thrombin induces an inflammatory phenotype in a human brain endothelial cell line , 2012, Journal of Neuroimmunology.

[7]  D. Strayer,et al.  Blood-Brain Barrier Abnormalities Caused by HIV-1 gp120: Mechanistic and Therapeutic Implications , 2012, TheScientificWorldJournal.

[8]  E. V. Van Bockstaele,et al.  HIV‐1 gp120 upregulates matrix metalloproteinases and their inhibitors in a rat model of HIV encephalopathy , 2011, The European journal of neuroscience.

[9]  E. Rosenberg,et al.  Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. , 2011, The Journal of infectious diseases.

[10]  N. Suzuki,et al.  Astrocytes and pericytes cooperatively maintain a capillary-like structure composed of endothelial cells on gel matrix , 2011, Brain Research.

[11]  M. Nonnemacher,et al.  Breaking down the barrier: The effects of HIV-1 on the blood–brain barrier , 2011, Brain Research.

[12]  E. Rosenberg,et al.  Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy. , 2011, The Journal of infectious diseases.

[13]  J. Clements,et al.  Human Immunodeficiency Virus Infection of Human Astrocytes Disrupts Blood–Brain Barrier Integrity by a Gap Junction-Dependent Mechanism , 2011, The Journal of Neuroscience.

[14]  R. Frausto,et al.  Astrocytic Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) Promotes Oligodendrocyte Differentiation and Enhances CNS Myelination , 2011, The Journal of Neuroscience.

[15]  S. Lewin,et al.  Plasma levels of soluble CD14 independently predict mortality in HIV infection. , 2011, The Journal of infectious diseases.

[16]  Dan J Stein,et al.  The neurobiology of HIV dementia: implications for practice in South Africa. , 2011, African journal of psychiatry.

[17]  B. Ances,et al.  Pathogenesis of HIV in the Central Nervous System , 2010, Current HIV/AIDS reports.

[18]  E. V. Van Bockstaele,et al.  HIV-1 gp120-Induced Injury to the Blood-Brain Barrier: Role of Metalloproteinases 2 and 9 and Relationship to Oxidative Stress , 2010, Journal of neuropathology and experimental neurology.

[19]  R. Bischoff,et al.  Physiology and pathophysiology of matrix metalloproteases , 2010, Amino Acids.

[20]  E. V. Bockstaele,et al.  Blood–brain barrier abnormalities caused by exposure to HIV-1 gp120 — Protection by gene delivery of antioxidant enzymes , 2010, Neurobiology of Disease.

[21]  D. Kolson,et al.  HIV-Associated Neurocognitive Disorder: Pathogenesis and Therapeutic Opportunities , 2010, Journal of Neuroimmune Pharmacology.

[22]  P. Couraud,et al.  Peripheral blood CD4+ T lymphocytes from multiple sclerosis patients are characterized by higher PSGL‐1 expression and transmigration capacity across a human blood‐brain barrier‐derived endothelial cell line , 2009, Journal of leukocyte biology.

[23]  S. Amini,et al.  Monocyte chemoattractant protein-1 (MCP-1): an overview. , 2009, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[24]  I. Grant,et al.  Cognitive Neuropsychology of HIV-Associated Neurocognitive Disorders , 2009, Neuropsychology Review.

[25]  G. Zoppo.  Inflammation and the neurovascular unit in the setting of focal cerebral ischemia , 2009, Neuroscience.

[26]  A. Małecki,et al.  Physiology and pharmacological role of the blood-brain barrier. , 2008, Pharmacological reports : PR.

[27]  D. Clifford.  HIV-associated neurocognitive disease continues in the antiretroviral era. , 2008, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[28]  W. Parks,et al.  Control of matrix metalloproteinase catalytic activity. , 2007, Matrix biology : journal of the International Society for Matrix Biology.

[29]  S. Crowe,et al.  Matrix metalloproteinases, their production by monocytes and macrophages and their potential role in HIV‐related diseases , 2006, Journal of leukocyte biology.

[30]  M. Bissell,et al.  Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. , 2006, Annual review of cell and developmental biology.

[31]  D. Douek,et al.  HIV disease: fallout from a mucosal catastrophe? , 2006, Nature Immunology.

[32]  J. Berman,et al.  CCL2/Monocyte Chemoattractant Protein-1 Mediates Enhanced Transmigration of Human Immunodeficiency Virus (HIV)-Infected Leukocytes across the Blood–Brain Barrier: A Potential Mechanism of HIV–CNS Invasion and NeuroAIDS , 2006, The Journal of Neuroscience.

[33]  R. Gallo,et al.  International NeuroAIDS: prospects of HIV-1 associated neurological complications , 2005, Cell Research.

[34]  K. Williams,et al.  The role of monocytes and perivascular macrophages in HIV and SIV neuropathogenesis: Information from non-human primate models , 2005, Neurotoxicity Research.

[35]  D. Hadjipavlou-Litina,et al.  Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results. , 2005, Current medicinal chemistry.

[36]  B. Haye,et al.  TIMPs as multifacial proteins. , 2004, Critical reviews in oncology/hematology.

[37]  Motoharu Seiki,et al.  Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. , 2003, Cancer letters.

[38]  J. Berman,et al.  Chemokine-dependent mechanisms of leukocyte trafficking across a model of the blood-brain barrier. , 2003, Methods.

[39]  Gillian Murphy,et al.  Metalloproteinase inhibitors: biological actions and therapeutic opportunities , 2002, Journal of Cell Science.

[40]  E. Masliah,et al.  The National NeuroAIDS Tissue Consortium:a new paradigm in brain banking with an emphasis on infectious disease , 2001, Neuropathology and applied neurobiology.

[41]  S. Lawn,et al.  Elevated serum concentrations of soluble CD14 in HIV− and HIV+ patients with tuberculosis in Africa: prolonged elevation during anti‐tuberculosis treatment , 2000, Clinical and experimental immunology.

[42]  M. Dowty,et al.  Design and synthesis of piperazine-based matrix metalloproteinase inhibitors. , 2000, Journal of medicinal chemistry.

[43]  J. Westermarck,et al.  Regulation of matrix metalloproteinase expression in tumor invasion , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[44]  G. Rosenberg,et al.  Matrix Metalloproteinases in Cerebrovascular Disease , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[45]  G. Rosenberg,et al.  Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. , 1998, Stroke.

[46]  V. Torri,et al.  Elevated cerebrospinal fluid levels of monocyte chemotactic protein‐1 correlate with HIV‐1 encephalitis and local viral replication , 1998, AIDS.

[47]  D. Gomez,et al.  Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. , 1997, European journal of cell biology.

[48]  A. Rehemtulla,et al.  Membrane Type Matrix Metalloproteinase 1 Activates Pro-gelatinase A without Furin Cleavage of the N-terminal Domain* , 1996, The Journal of Biological Chemistry.

[49]  T. Crawford,et al.  Cerebral white matter changes in acquired immunodeficiency syndrome dementia: Alterations of the blood‐brain barrier , 1993, Annals of neurology.

[50]  E. Kay,et al.  Neuropathologic findings in AIDS and human immunodeficiency virus infection — Report on 30 patients , 1991, Irish journal of medical science.

[51]  B. Brew,et al.  HIV-associated neurocognitive disorder. , 2018, Handbook of clinical neurology.

[52]  Colin McCann,et al.  PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS Discoidin domain receptor 2 regulates neutrophil chemotaxis in 3D collagen matrices , 2017 .

[53]  R. Fridman,et al.  Assessment of gelatinases (MMP-2 and MMP-9) by gelatin zymography. , 2012, Methods in molecular biology.

[54]  R. Kizek,et al.  Matrix metalloproteinases. , 2010, Current medicinal chemistry.

[55]  M. Balda,et al.  Tight junctions: molecular architecture and function. , 2006, International Review of Cytology.

[56]  B. Fiedler,et al.  Interference of antihypertrophic molecules and signaling pathways with the Ca2+-calcineurin-NFAT cascade in cardiac myocytes. , 2004, Cardiovascular research.

[57]  M. Vincenti.  The matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) genes. Transcriptional and posttranscriptional regulation, signal transduction and cell-type-specific expression. , 2001, Methods in molecular biology.

[58]  FLUIDS AND BARRIERS OF THE CNS REVIEW Open Access , 2022 .

[59]  M. Kaul,et al.  Open Access Review Molecular Mechanisms of Neuroinvasion by Monocytes-macrophages in Hiv-1 Infection , 2022 .